VORAXAZE
Total Payments
$3.7M
Transactions
1,483
Doctors
635
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $379,812 | 176 | 71 |
| 2023 | $579,372 | 260 | 133 |
| 2022 | $533,733 | 191 | 86 |
| 2021 | $887,344 | 137 | 69 |
| 2020 | $662,711 | 85 | 17 |
| 2019 | $489,075 | 282 | 103 |
| 2018 | $104,557 | 211 | 152 |
| 2017 | $18,416 | 141 | 111 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.1M | 37 | 58.7% |
| Consulting Fee | $711,036 | 49 | 19.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $394,831 | 146 | 10.8% |
| Education | $187,708 | 17 | 5.1% |
| Travel and Lodging | $81,783 | 266 | 2.2% |
| Food and Beverage | $52,765 | 932 | 1.4% |
| Grant | $30,900 | 14 | 0.8% |
| Space rental or facility fees (teaching hospital only) | $27,825 | 16 | 0.8% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $16,592 | 4 | 0.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,268 | 2 | 0.1% |
Payments by Type
Research
$2.1M
37 transactions
General
$1.5M
1,446 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Voraxaze Rescue Use Data | BTG International, Inc. | $624,792 | 0 |
| VORAXAZE | BTG International, Inc. | $273,768 | 0 |
| An Open-Label, Multi-Institutional Phase 0 Study to Assess the Use of Glucarpidase in Patients with Osteosarcoma Receiving High-Dose Methotrexate | BTG International, Inc. | $194,835 | 0 |
| Pilot Study of glucarpidase in Patients with Central Nervous System Lymphoma | BTG International, Inc. | $165,714 | 0 |
| LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | BTG International, Inc. | $126,058 | 0 |
| A Pilot Study of Voraxaze glucarpidase in Patietns with Central Nervous System Lymphoma | BTG International, Inc. | $123,114 | 0 |
| An Open-Label Pilot Study to Assess the Use of Glucarpidase in Patients with Osteosarcoma Receiving High-Dose Methotrexate | BTG International, Inc. | $106,285 | 0 |
| An Open-Label, Multi-Institutional Pilot Study to Assess the Use of Glucarpidase in Patients with Osteosarcoma Receiving High-Dose Methotrexate | BTG International, Inc. | $101,272 | 0 |
| Voraxaze Planned Use Research | BTG International, Inc. | $98,280 | 0 |
| Prediction, Early Detection, and Treatment of Methotrexate-associated Acute Kidney Injury | BTG International, Inc. | $89,100 | 0 |
| Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma | BTG International, Inc. | $82,738 | 0 |
| Anti-tumor study of Glucarpidase with MTHFD2 inhibitor against blood cancer xenograft | BTG International, Inc. | $79,999 | 0 |
| Combination Study of Voraxaze with methylene terahydrofolate dehydrogenase 2 inhibition | BTG International, Inc. | $37,408 | 0 |
| Retrospective Review of High Dose Methotrexate Regimen in CNS Lymphoma Treatment | BTG International, Inc. | $22,793 | 0 |
| Rechallenge with Methotrexate after Administration of Glucarpidase for Methotrexate-Associated Acute Kidney Injury | BTG International, Inc. | $21,157 | 0 |
Top Doctors Receiving Payments for VORAXAZE — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , N.P | Hematology & Oncology | Oakland, CA | $461.46 | 4 |
| , NP | Adult Health | Duarte, CA | $362.45 | 3 |
| , DNP, APRN-CNS, AOCNS | Oncology | Baltimore, MD | $268.07 | 2 |
| , M.D | Emergency Medicine | Smithtown, NY | $250.00 | 1 |
| , M.D | Pediatrics | San Antonio, TX | $245.61 | 2 |
| Lorraine Le Stephens | Family | Yorba Linda, CA | $238.34 | 2 |
| Myra Woolery | Pediatrics | Bethesda, MD | $237.39 | 2 |
| Michelle Miller | Physician Assistant | Tampa, FL | $221.51 | 2 |
| , M.D | Hematology & Oncology | Loma Linda, CA | $219.44 | 2 |
| , NP | Registered Nurse | New Orleans, LA | $219.35 | 2 |
| , M.D | Pediatric Hematology-Oncology | Corpus Christi, TX | $216.65 | 3 |
| , MD | Pediatrics | New Orleans, LA | $214.60 | 3 |
| , MD | Pediatric Hematology-Oncology | New Orleans, LA | $214.60 | 3 |
| , M.D | Pediatrics | Dallas, TX | $207.44 | 2 |
| , M.D | Pediatric Hematology-Oncology | Mcallen, TX | $205.15 | 2 |
| , PA-C | Physician Assistant | New Orleans, LA | $204.47 | 2 |
| , PNP | Pediatrics | Washington, DC | $203.73 | 2 |
| , APRN, AGNP-C | Nurse Practitioner | Orlando, FL | $195.24 | 2 |
| , APRN | Pediatrics | Lexington, KY | $192.40 | 2 |
| , NP | Nurse Practitioner | Hackensack, NJ | $170.92 | 2 |
| , MD | Internal Medicine | Houston, TX | $154.56 | 3 |
| , MD | Internal Medicine | Jasper, AL | $148.72 | 1 |
| , PA-C | Medical | Baltimore, MD | $148.72 | 1 |
| , CRNP | Nurse Practitioner | Baltimore, MD | $148.72 | 1 |
| , DO | Hematology & Oncology | West Reading, PA | $148.08 | 7 |
Ad
Manufacturing Companies
- BTG International, Inc. $3.2M
- BTG INTERNATIONAL, INC. $388,944
- Biocompatibles, Inc. $16,310
Product Information
- Type Drug
- Total Payments $3.7M
- Total Doctors 635
- Transactions 1,483
About VORAXAZE
VORAXAZE is a drug associated with $3.7M in payments to 635 healthcare providers, recorded across 1,483 transactions in the CMS Open Payments database. The primary manufacturer is BTG International, Inc..
Payment data is available from 2017 to 2024. In 2024, $379,812 was paid across 176 transactions to 71 doctors.
The most common payment nature for VORAXAZE is "Unspecified" ($2.1M, 58.7% of total).
VORAXAZE is associated with 15 research studies, including "Voraxaze Rescue Use Data" ($624,792).